Holen Sie sich die Stockscreener-App
45.43
1.11%
0.50
Handel nachbörslich:
45.43
Schlusskurs vom Vortag:
$44.93
Offen:
$44.99
24-Stunden-Volumen:
597.39K
Relative Volume:
0.75
Marktkapitalisierung:
$2.55B
Einnahmen:
$651.97M
Nettoeinkommen (Verlust:
$59.71M
KGV:
42.47
EPS:
1.0696
Netto-Cashflow:
$172.03M
1W Leistung:
+0.13%
1M Leistung:
+22.62%
6M Leistung:
+43.54%
1J Leistung:
+29.80%
1-Tages-Spanne:
$44.68
$45.50
1-Wochen-Bereich:
$44.10
$45.94
52-Wochen-Spanne:
$29.16
$45.94
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Vergleichen Sie SUPN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
45.43 | 2.50B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
153.20 | 67.75B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.29 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.84 | 43.70B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.48 | 21.51B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
380.47 | 18.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
How sentiment analysis helps forecast Supernus Pharmaceuticals Inc.July 2025 Setups & High Yield Equity Trading Tips - Newser
Analyzing recovery setups for Supernus Pharmaceuticals Inc. investorsFed Meeting & Advanced Technical Analysis Signals - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
Will earnings trigger a reversal in Supernus Pharmaceuticals Inc.July 2025 Summary & Safe Capital Preservation Plans - Newser
Will Supernus Pharmaceuticals Inc. benefit from seasonalityMarket Sentiment Review & Reliable Entry Point Alerts - khodrobank.com
Real time breakdown of Supernus Pharmaceuticals Inc. stock performanceNew Guidance & Intraday High Probability Alerts - Newser
Risk vs reward if holding onto Supernus Pharmaceuticals Inc.July 2025 Pullbacks & High Conviction Buy Zone Alerts - Newser
Predicting Supernus Pharmaceuticals Inc. trend using moving averagesBond Market & Long-Term Safe Investment Plans - Newser
Custom strategy builders for tracking Supernus Pharmaceuticals Inc.July 2025 Final Week & Technical Pattern Recognition Alerts - Newser
How to build a custom watchlist for Supernus Pharmaceuticals Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Sector ETF performance correlation with Supernus Pharmaceuticals Inc.2025 Price Action Summary & AI Driven Price Predictions - Newser
Candlestick signals on Supernus Pharmaceuticals Inc. stock today2025 Technical Patterns & Real-Time Buy Signal Notifications - Newser
Has Supernus Pharmaceuticals Inc. found a price floorMarket Risk Summary & Safe Capital Growth Trade Ideas - Newser
Supernus Pharmaceuticals stock hits 52-week high at $45.85 - Investing.com
Supernus Pharmaceuticals stock hits 52-week high at $45.85 By Investing.com - Investing.com UK
Can Supernus Pharmaceuticals Inc. expand into new marketsMarket Weekly Review & Low Drawdown Investment Strategies - khodrobank.com
EV Market: What are Supernus Pharmaceuticals Inc.’s recent SEC filings showingPortfolio Return Report & Detailed Earnings Play Strategies - khodrobank.com
Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio - Yahoo Finance
Using data filters to optimize entry into Supernus Pharmaceuticals Inc.Earnings Recap Report & Fast Entry Momentum Alerts - Newser
Is Supernus Pharmaceuticals Inc. stock showing strong momentum2025 Biggest Moves & Daily Profit Maximizing Tips - khodrobank.com
What technical models suggest about Supernus Pharmaceuticals Inc.’s comebackPrice Action & Reliable Entry Point Trade Alerts - Newser
Market Outlook: What is the long term forecast for Supernus Pharmaceuticals Inc. stockBear Alert & Safe Entry Momentum Stock Tips - khodrobank.com
What are Supernus Pharmaceuticals Inc.’s earnings expectations2025 Volume Leaders & Daily Technical Stock Forecast Reports - khodrobank.com
Is Supernus Pharmaceuticals Inc. benefiting from interest rate changesJuly 2025 Chart Watch & High Win Rate Trade Tips - khodrobank.com
How to use a screener to detect Supernus Pharmaceuticals Inc. breakoutsEarnings Risk Report & Community Driven Trade Alerts - Newser
Published on: 2025-08-31 13:29:05 - Newser
Recovery Signals Appearing in Supernus Pharmaceuticals Inc. Charts getLinesFromResByArray error: size == 0 - 더경남뉴스
Regression analysis insights on Supernus Pharmaceuticals Inc. performance2025 Winners & Losers & Free Safe Capital Growth Stock Tips - Newser
Historical volatility pattern of Supernus Pharmaceuticals Inc. visualizedJuly 2025 PostEarnings & AI Based Buy/Sell Signal Reports - Newser
Technical analysis overview for Supernus Pharmaceuticals Inc. stockJuly 2025 Trade Ideas & Stock Portfolio Risk Management - Newser
Can Supernus Pharmaceuticals Inc. Regain Momentum After BreakdownJuly 2025 Setups & Smart Allocation Stock Reports - beatles.ru
How institutional ownership impacts Supernus Pharmaceuticals Inc. stock2025 Year in Review & Verified Stock Trade Ideas - Newser
Candlestick Reversal Detected on Supernus Pharmaceuticals Inc.’s ChartJuly 2025 Movers & Weekly Sector Rotation Insights - beatles.ru
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
Aug 27 '25 |
Option Exercise |
12.98 |
17,195 |
223,191 |
1,088,654 |
| Khattar Jack A. | President, CEO |
Aug 28 '25 |
Sale |
45.12 |
24,150 |
1,089,648 |
1,092,633 |
| Khattar Jack A. | President, CEO |
Aug 27 '25 |
Sale |
45.05 |
10,650 |
479,782 |
1,078,004 |
| NEWHALL CHARLES W III | Director |
Aug 27 '25 |
Sale |
45.01 |
3,588 |
161,496 |
129,644 |
3.60%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):